Focused On-demand Library for CD209 antigen

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9NNX6

UPID:

CD209_HUMAN

Alternative names:

C-type lectin domain family 4 member L; Dendritic cell-specific ICAM-3-grabbing non-integrin 1

Alternative UPACC:

Q9NNX6; A8KAM4; A8MVQ9; G5E9C4; Q2TB19; Q96QP7; Q96QP8; Q96QP9; Q96QQ0; Q96QQ1; Q96QQ2; Q96QQ3; Q96QQ4; Q96QQ5; Q96QQ6; Q96QQ7; Q96QQ8

Background:

The CD209 antigen, also known as C-type lectin domain family 4 member L or Dendritic cell-specific ICAM-3-grabbing non-integrin 1, plays a pivotal role in the immune system. It functions as a pathogen-recognition receptor on immature dendritic cells, facilitating the endocytosis of pathogens for degradation. This process is crucial for the initiation of the primary immune response, including the presentation of pathogen-derived antigens to T-cells, thereby activating the adaptive immune response. Additionally, CD209 acts as an attachment receptor for various pathogens, including HIV, Ebolavirus, and Influenzavirus A, highlighting its significance in microbial infection defense.

Therapeutic significance:

Understanding the role of CD209 antigen could open doors to potential therapeutic strategies.